Tag - Corbus Pharmaceuticals

Corbus Pharmaceuticals Updates Data from Lenabasum Open-Label Extension Studies in Systemic Sclerosis and Dermatomyositis at 2019 ACR Annual Meeting

Ziad2022-11-25T14:03:26-05:00 Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced continued favorable safety and efficacy outcomes in open-label extensions (OLE) of lenabasum Phase 2 studies in two rare and serious autoimmune diseases: systemic sclerosis (SSc) and dermatomyositis (DM). Read more >>

Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2019 ACR Annual Meeting

Ziad2022-11-25T14:03:26-05:00 Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, announced the presentation of three abstracts at the American College of Rheumatology (“ACR”) 2019 Annual Meeting being held November 8-13, 2019 in Atlanta, Georgia. Read more >>

Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in May

Ziad2022-11-25T14:03:38-05:00 Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company focused on treating inflammatory and fibrotic diseases by targeting the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present at two upcoming investor conferences in May. Read more >>

Corbus Pharmaceuticals Completes Enrollment of RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis

Ziad2022-11-25T14:03:38-05:00 Corbus Pharmaceuticals Holdings, Inc. today announced the completion of subject enrollment in RESOLVE-1, a Phase 3 study assessing the efficacy and safety of lenabasum for the treatment of systemic sclerosis (SSc). The Company expects to report topline results from this study in the summer of 2020. These data are anticipated to support an initial marketing application for lenabasum. Read more >>

Corbus Pharmaceuticals Appoints Rachelle Jacques to Board of Directors

Ziad2022-11-25T14:03:38-05:00 Corbus Pharmaceuticals Holdings, Inc. today announced the appointment of Rachelle Jacques to its Board of Directors. <a href="https://www.globenewswire.com/news-release/2019/04/08/1799009/0/en/Corbus-Pharmaceuticals-Appoints-Rachelle-Jacques-to-Board-of-Directors.html" target="_blank">Read more >></a>

Corbus Pharmaceuticals Provides Management Team Updates

Ziad2022-11-25T14:03:38-05:00 Corbus Pharmaceuticals Holdings, Inc. today announced several changes to its management team. Read more >>

Corbus Pharmaceuticals Announces Appointment of Craig Millian as Chief Commercial Officer

Ziad2022-11-25T14:03:39-05:00 Corbus Pharmaceuticals Holdings, Inc. today announced the appointment of Craig Millian as Chief Commercial Officer, effective February 28, 2019. Read more >>

Corbus Pharmaceuticals Announces Strategic Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Lenabasum in Japan for Systemic Sclerosis and Dermatomyositis

Ziad2022-11-25T14:04:53-05:00Corbus Pharmaceuticals Holdings, Inc. announced today that they have entered into a strategic collaboration with Kaken Pharmaceutical Co., Ltd. ("Kaken") for the development and commercialization in Japan of Corbus' investigational drug lenabasum for the treatment of systemic sclerosis ("SSc") and dermatomyositis ("DM"), two rare and serious autoimmune diseases. Read more >>

Corbus Pharma (CRBP) Announces Issuance of Composition of Matter Patent Related to Lenabasum

Ziad2022-11-25T14:04:53-05:00Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical stage drug development company with the industry’s leading pipeline focused on treating inflammatory and fibrotic diseases by targeting the endocannabinoid system, announced today that the U.S. Patent and Trademark Office (“USPTO”) issued Patent No. 10,154,986 to the Company which claims pharmaceutical compositions of lenabasum through 2034. Read more >>

Corbus Pharmaceuticals Presents Lenabasum Long-Term Open-Label Clinical Data Showing Maintenance of Favorable Safety Profile and Further Improvement in Multiple Efficacy Endpoints in Systemic Sclerosis and Dermatomyositis Phase 2 Studies

Ziad2022-11-25T14:04:54-05:00Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company with the industry’s leading pipeline focused on treating inflammatory and fibrotic diseases by targeting the endocannabinoid system, today announced continued favorable safety and tolerability profiles and further improvement in efficacy outcomes in open-label extensions (OLEs) of lenabasum Phase 2 studies in two rare and serious autoimmune diseases, systemic sclerosis (SSc) and dermatomyositis (DM). Read more >>